Literature DB >> 26112491

Physical and functional interaction between hepatitis C virus NS5A protein and ovarian tumor protein deubiquitinase 7B.

Imelda Rosalyn Sianipar1,2, Chieko Matsui1, Nanae Minami1, Xiang Gan3, Lin Deng1, Hak Hotta1, Ikuo Shoji1.   

Abstract

Hepatitis C virus (HCV) NS5A protein plays crucial roles in viral RNA replication, virus assembly, and viral pathogenesis. Although NS5A has no known enzymatic activity, it modulates various cellular pathways through interaction with cellular proteins. HCV NS5A (and other HCV proteins) are reportedly degraded through the ubiquitin-proteasome pathway; however, the physiological roles of ubiquitylation and deubiquitylation in HCV infection are largely unknown. To elucidate the role of deubiquitylation in HCV infection, an attempt was made to identify a deubiquitinase (DUB) that can interact with NS5A protein. An ovarian tumor protein (OTU), deubiquitinase 7B (OTUD7B), was identified as a novel NS5A-binding protein. Co-immunoprecipitation analyses showed that NS5A interacts with OTUD7B in both Huh-7 and HCV RNA replicon cells. Immunofluorescence staining revealed that HCV NS5A protein colocalizes with OTUD7B in the cytoplasm. Moreover, HCV infection was found to enhance the nuclear localization of OTUD7B. The OTUD7B-binding domain on NS5A was mapped using a series of NS5A deletion mutants. The present findings suggest that the domain I of NS5A is important and the region from amino acid 121 to 126 of NS5A essential for the interaction. Either V121A or V124A mutation in NS5A disrupts the NS5A-OTUD7B interaction. The results of this in vivo ubiquitylation assay suggest that HCV NS5A enhances OTUD7B DUB activity. Taken together, these results suggest that HCV NS5A protein interacts with OTUD7B, thereby modulating its DUB activity.
© 2015 The Societies and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  NS5A; deubiquitinase; hepatitis C virus; ovarian tumor protein deubiquitinase 7B

Mesh:

Substances:

Year:  2015        PMID: 26112491     DOI: 10.1111/1348-0421.12278

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  7 in total

1.  Nonstructural Protein 5A Impairs DNA Damage Repair: Implications for Hepatitis C Virus-Mediated Hepatocarcinogenesis.

Authors:  Tram T T Nguyen; Eun-Mee Park; Yun-Sook Lim; Soon B Hwang
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

2.  OTUD7B deubiquitinates SQSTM1/p62 and promotes IRF3 degradation to regulate antiviral immunity.

Authors:  Weihong Xie; Shuo Tian; Jiahui Yang; Sihui Cai; Shouheng Jin; Tao Zhou; Yaoxing Wu; Zhiyun Chen; Yanqin Ji; Jun Cui
Journal:  Autophagy       Date:  2022-01-31       Impact factor: 13.391

Review 3.  The Role of Deubiquitinases in Oncovirus and Host Interactions.

Authors:  Yueshuo Li; Feng Shi; Jianmin Hu; Longlong Xie; Ann M Bode; Ya Cao
Journal:  J Oncol       Date:  2019-07-18       Impact factor: 4.375

Review 4.  The Role of Chaperone-Mediated Autophagy in Hepatitis C Virus-Induced Pathogenesis.

Authors:  Chieko Matsui; Putu Yuliandari; Lin Deng; Takayuki Abe; Ikuo Shoji
Journal:  Front Cell Infect Microbiol       Date:  2021-12-02       Impact factor: 5.293

5.  Hepatitis C Virus NS5A Protein Promotes the Lysosomal Degradation of Hepatocyte Nuclear Factor 1α via Chaperone-Mediated Autophagy.

Authors:  Chieko Matsui; Lin Deng; Nanae Minami; Takayuki Abe; Kazuhiko Koike; Ikuo Shoji
Journal:  J Virol       Date:  2018-06-13       Impact factor: 5.103

Review 6.  Virological Mechanisms in the Coinfection between HIV and HCV.

Authors:  Maria Carla Liberto; Emilia Zicca; Grazia Pavia; Angela Quirino; Nadia Marascio; Carlo Torti; Alfredo Focà
Journal:  Mediators Inflamm       Date:  2015-10-01       Impact factor: 4.711

7.  Stability of Begomoviral pathogenicity determinant βC1 is modulated by mutually antagonistic SUMOylation and SIM interactions.

Authors:  Ashwin Nair; Kiran Sankar Chatterjee; Vikram Jha; Ranabir Das; P V Shivaprasad
Journal:  BMC Biol       Date:  2020-08-31       Impact factor: 7.431

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.